Microdosing Ketamine for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Microdosing Ketamine for Health & Longevity

Created on 06/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Microdosing ketamine means taking very small, often unnoticeable, repeated doses of an anesthetic that, at higher single doses, can rapidly ease severe depression. Whether the much smaller repeated doses deliver the same benefit is far less certain, with smaller, slower, shorter-lasting effects. Repeated dosing carries real concerns: bladder damage, dependence, raised blood pressure, and possible memory problems. (Full Review)

Protocol

Dose
0.5–2 mg/kg
Low-dose oral or sublingual ketamine
Schedule
Once to a few times weekly
Spaced schedule, not a true daily microdose
Adjunct Use
With antidepressant and psychotherapy
Often given as an add-on rather than alone
Time to effect
Durable mood change
2–6 weeks
With repeated low-dose oral regimens
Acute mood effects
Within hours
From a perceptible dose

Benefits

Contraindications
  • Uncontrolled hypertension
  • Significant cardiovascular disease (recent myocardial infarction within ~90 days, unstable angina, aneurysm)
  • History of psychosis or schizophrenia
  • Active or prior substance use disorder
  • Pre-existing bladder pathology or significant liver disease (cirrhosis)
  • Pregnant or breastfeeding
    •
Key Interactions
  • CNS depressants (benzodiazepines such as diazepam, opioids, alcohol)
  • Benzodiazepines specifically
  • Other blood-pressure-raising agents (stimulants, certain decongestants, monoamine oxidase inhibitors)
  • CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice)
  • CYP3A4/CYP2B6 inducers (rifampin, carbamazepine, St. John's Wort)
  • Serotonergic agents and other antidepressants (SSRIs and SNRIs)
  • Sedating supplements (valerian, kava, high-dose magnesium, cannabidiol); stimulant supplements
  • Other dissociatives or psychedelics
    •

Risk & Side Effects

  • High: Acute dissociation and psychotomimetic effects; hemodynamic effects
    •
  • Medium: Ketamine-induced uropathy; dependence, tolerance, and misuse potential; cognitive impairment with repeated use
    •
  • Low: Hepatobiliary effects; nausea, dizziness, and sedation
    •
  • Speculative: Long-term neuropsychiatric effects of chronic sub-perceptual use
    •

Monitoring

Marker Target Why
Blood Pressure <120/80 mmHg at baseline Ketamine reliably raises blood pressure
eGFR (kidney filtration) >90 mL/min/1.73m² Detect cumulative kidney/urinary toxicity
ALT/AST (liver enzymes) <25 U/L Detect hepatobiliary effects of repeated dosing
Urinalysis / urinary symptom score No blood, no urgency, normal capacity Early detection of ketamine-induced uropathy
Depression rating (e.g., PHQ-9 score) <5 (minimal) Quantify whether the mood benefit justifies continued exposure

Cadence: Blood pressure around each dosing session; structured mood and urinary-symptom review at ~4 weeks; kidney, liver, and bladder/urinary reassessment every 3–6 months for continued use, with more frequent checks if symptoms emerge.

Qualitative Assessment

  • Mood, motivation, and anhedonia (loss of pleasure) improvement
  • Sleep quality and daytime energy
  • Cognitive clarity and memory (watching for decline with repeated use)
  • Urinary comfort (urgency, frequency, discomfort as early uropathy signs)
  • Absence of craving or escalating desire to dose
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.